Pilot study of tocilizumab monotherapy for active chronic periaortitis
Authors' conclusion
Our study showed that TCZ monotherapy contributed to remarkable clinical and laboratory improvement in CP patients and could be an alternative treatment option for CP.
Study context
- Population
- Patients with definite or possible chronic periaortitis (CP) at acute active stage
- Participants
- 12 patients
- Outcome
- Rate of partial and complete remission after 3 months TCZ monotherapy
- Follow-up
- 3 months
Methodological detailssingle-arm, open-label
- Single-arm
- Open-label
Main finding
As reported in the abstract
Remission after 3 months TCZ
Partial remission
3
27.3%
Complete remission
7
63.6%
Total remission rate
90.9%
Secondary outcomes
Clinical symptoms, inflammatory markers and CT perivascular mass
- Shrinkage of perivascular mass ≥50% on CT
- 9 (81.8%)
- All patients reported improvement in clinical symptoms
- ESR and CRP decreased to normal levels after TCZ
Original publication
Pilot study of tocilizumab monotherapy for active chronic periaortitis. RMD Open. Published 28 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →